SCHEMBL30380236

SCHEMBL30380236

C[C@H](Cc1nccs1)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC6A3 Q01959 2/20 0.53
▸ MAOB P27338 4/20 0.44
▸ MAOA P21397 3/20 0.44
▸ NISCH Q9Y2I1 3/20 0.44
▸ FDPS P14324 1/20 0.44
▸ LMNA P02545 2/20 0.41
▸ TSHR P16473 1/20 0.41
▸ TAAR1 Q96RJ0 3/20 0.41
▸ KDM1A O60341 1/20 0.39
▸ PDPK1 O15530 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ NR3C2 P08235 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.38
▸ AOC3 Q16853 1/20 0.38
▸ SCN1A P35498 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Thiophene SCHEMBL28462151 0.94 SLC6A3 (0.48) SLC6A3MAOBMAOANISCHFDPS
SCHEMBL31570743 0.84 SLC6A3 (0.57) SLC6A3MAOBNISCHFDPSLMNA
SCHEMBL8034456 0.79 GRIN2D (0.53) SLC6A3MAOBFDPSKDM1APDPK1
SCHEMBL8722436 0.79 GRIN2D (0.53) SLC6A3MAOBFDPSKDM1APDPK1
SCHEMBL23771310 0.78 TSHR (0.50) SLC6A3MAOBFDPSLMNATSHR
SCHEMBL104654 0.75 — —
SCHEMBL28307500 0.73 SLC6A3 (0.40) SLC6A3MAOBMAOANISCHLMNA
SCHEMBL27722097 0.72 SLC6A3 (0.49) SLC6A3MAOBFDPSLMNATSHR
SCHEMBL5544952 0.72 — —
SCHEMBL18875017 0.72 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12540134-B2 Inhibitors of adrenoreceptor ADRAC2 BAYER AKTIENGESELLSCHAFT (DE) 2026-02-03 — — US disclosed
US-20230115270-A1 INHIBITORS OF ADRENORECEPTOR ADRAC2 BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12540134-B2 Inhibitors of adrenoreceptor ADRAC2 ADRA2C, ADRB3, ADRB2 SLC6A3 632/4885MAOB 1401/4885MAOA 1169/4885
US-20230115270-A1 INHIBITORS OF ADRENORECEPTOR ADRAC2 ADRA2C, ADRB2, ADRB3 SLC6A3 1043/4885MAOB 1536/4885MAOA 1471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback